Piyush Poddar, MD
Internal Medicine · Cleveland, OHNPI 1104132554
Payments from drug & device makers
Across 29 payments — averaging $37.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$214
- Johnson & Johnson$183
- Bristol Myers Squibb$160
- AstraZeneca$158
- Mallinckrodt Enterprises LLC$111
- Mallinckrodt Hospital Products Inc.$95
- plus $161 from 6 others
What the payments were for
- Food & beverage$1,083100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 7 | $214 |
| Johnson & Johnson | 6 | $183 |
| Bristol Myers Squibb | 2 | $160 |
| AstraZeneca | 2 | $158 |
| Mallinckrodt Enterprises LLC | 2 | $111 |
| Mallinckrodt Hospital Products Inc. | 2 | $95 |
| AbbVie | 3 | $60 |
| GSK | 1 | $41 |
| Boehringer Ingelheim | 1 | $22 |
| Aurinia Pharma U.S., Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Pfizer | 1 | $12 |
How this compares
$1,083 in reported general payments places this provider in the 75th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 86 | $3,455 |
| Prednisone | 290 | $2,102 |
| MethotrexateMethotrexate Sodium | 99 | $2,011 |
| Gabapentin | 47 | $826 |
| Mycophenolate Mofetil | 11 | $773 |
| Colchicine | 22 | $739 |
| Sulfasalazine | 32 | $593 |
| Leflunomide | 12 | $434 |
| Allopurinol | 17 | $198 |
| Methotrexate SodiumMethotrexate Sodium/Pf | 12 | $186 |
| Alendronate Sodium | 21 | $174 |
| Folic Acid | 25 | $166 |
| Celecoxib | 12 | $166 |
| Cyclobenzaprine Hcl | 19 | $148 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Cleveland
- Vadim KoshkinCleveland$6.1M
- Emily LittlejohnCleveland$885K
- Marina MagreyCleveland$856K
- Pushkar KanadeCleveland$753K
- Cyrus HarrisCleveland$726K
- Ila TamaskarCleveland$721K
- Amar KrishnaswamyCleveland$552K
- Albree Tower-RaderCleveland$522K
- Adriano TonelliCleveland$464K
- Mahboob RahmanCleveland$409K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.